FDA Approval for PAVBLU issued to AMGEN INC
Stocks in this Quantisnow insightHealth Care
Historical context for AMGN
Across the 20 sessions after earlier AMGN headlines, the stock closed higher 9 times and lower 11 times, with a median move of 1.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | AMGN | SPY |
|---|---|---|---|
| Oct 21, 2026 | AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026 | -0.1% | +0.5% |
| Oct 20, 2026 | TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS | +3.3% | +0.3% |
| Oct 12, 2026 | FDA Approval for REPATHA issued to AMGEN INC | +0.7% | -0.1% |
| Sep 30, 2026 | FDA Approval for RIABNI issued to AMGEN INC | -0.5% | -0.2% |
| Sep 22, 2026 | AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE | +4.3% | -0.0% |
| Sep 15, 2026 | FDA Approval for IMDELLTRA issued to AMGEN INC | -1.5% | -0.5% |
Quantisnow market dataNASDAQ
AMGN
Amgen Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 1983
Get push alerts for AMGN
Full AMGN profile on Quantisnow Follow AMGN and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time